TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate Safety, Immunogenicity and Efficacy of GSK Biologicals HPV-16/18 L1/AS04 Vaccine Administered Intramuscularly According to a Three-dose Schedule (0, 1, 6 Month) in Healthy Adult Female Subjects Aged 26 Years and Above
Brief Summary: This is a multicentre study in which women were planned to receive either the Human Papillomavirus Vaccine (HPV) vaccine or control. Under Protocol Amendment 3, study participation will last approximately 48 months and involves a total of eleven scheduled visits. Under Protocol Amendment 4, study participation will last up to 84 months and involves a maximum of seventeen scheduled visits.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: Aluminium Hydroxide Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo control | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Placebo control; Assigned to Arm(s): Aluminium Hydroxide Group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Comparator: HPV 16 L1 Vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Intervention Type: BIOLOGICAL; Name: Comparator: HPV 16 L1 Vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2
C: Arm Label: qHPV Vaccine in Base Study; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: Placebo in Base Study; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: qHPV Vaccine in Extension Study; Type: EXPERIMENTAL; Interventions: Biological: V501 | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): qHPV Vaccine in Base Study, qHPV Vaccine in Extension Study | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): Placebo in Base Study
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group F; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cervarix TM | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV vaccine (GSK1674330A); Assigned to Arm(s): Group A, Group B, Group C, Group D, Group E | Intervention Type: BIOLOGICAL; Name: Cervarix TM; Assigned to Arm(s): Group F

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind Comparison of Omacor and Placebo in Patients Awaiting Endarterectomy to Investigate the Effect on Carotid Plaque Stability
Brief Summary: The purpose of this study is to investigate the effect of intake of Omacor (Omega-3-acid ethyl ester 90) 2g/day on specified parameters related to the stability of carotid plaque in patients awaiting endarterectomy.


Options:
A: Intervention Type: DRUG; Name: Omega-3-acid ethyl ester 90 (n-3 PUFA); Assigned to Arm(s): N/A
B: Arm Label: EPA + DHA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: EPA + DHA plus ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: margarine spread | Intervention Type: DIETARY_SUPPLEMENT; Name: margarine spread; Assigned to Arm(s): ALA, EPA + DHA, EPA + DHA plus ALA, Placebo
C: Intervention Type: PROCEDURE; Name: Supplementation with fish oil versus placebo; Assigned to Arm(s): N/A
D: Arm Label: fish oil , corn oil; Type: EXPERIMENTAL; Interventions: Drug: Omega Three Polyunsaturated fatty acids | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Omega Three Polyunsaturated fatty acids | Intervention Type: DRUG; Name: Omega Three Polyunsaturated fatty acids; Assigned to Arm(s): fish oil , corn oil, placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind Comparison of Omacor and Placebo in Patients Awaiting Endarterectomy to Investigate the Effect on Carotid Plaque Stability
Brief Summary: The purpose of this study is to investigate the effect of intake of Omacor (Omega-3-acid ethyl ester 90) 2g/day on specified parameters related to the stability of carotid plaque in patients awaiting endarterectomy.


Options:
A: Arm Label: Insulin glargine + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: omega-3 polyunsaturated fatty acids (PUFA), Device: reusable pen device for insulin injection | Arm Label: Insulin glargine + placebo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: placebo, Device: reusable pen device for insulin injection | Arm Label: Standard care + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: omega-3 polyunsaturated fatty acids (PUFA) | Arm Label: Standard care + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: insulin glargine (HOE901); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo | Intervention Type: DRUG; Name: omega-3 polyunsaturated fatty acids (PUFA); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Standard care + omega-3 polyunsaturated fatty acids | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Insulin glargine + placebo, Standard care + placebo | Intervention Type: DEVICE; Name: reusable pen device for insulin injection; Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo
B: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil
C: Intervention Type: DRUG; Name: Omega-3-acid ethyl ester 90 (n-3 PUFA); Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: Supplementation with fish oil versus placebo; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pacemaker Remote Follow-up Evaluation and Review
Brief Summary: The purpose of the study is to compare remote pacemaker follow-up to current standard of care follow-up. The study will compare the rate of first diagnosis of clinically actionable events between patients who utilize the Medtronic Carelink® Network (Remote arm) versus patients who are followed via routine office visits augmented by transtelephonic monitoring (TTM)(Control arm).


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Drug: Insulin glulisine, Drug: Insulin glargine, Drug: Metformin | Arm Label: 2; Type: OTHER; Interventions: Drug: Insulin glulisine, Drug: Insulin glargine, Drug: Metformin | Intervention Type: DRUG; Name: Insulin glulisine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2
B: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Device: telemedicine program | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: telemedicine program; Assigned to Arm(s): Telemedicine
C: Arm Label: Arm 1: PE via telemedicine; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedicine | Arm Label: Arm 2: PE in person; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: In Person | Intervention Type: BEHAVIORAL; Name: Telemedicine; Assigned to Arm(s): Arm 1: PE via telemedicine | Intervention Type: BEHAVIORAL; Name: In Person; Assigned to Arm(s): Arm 2: PE in person
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Transtelephonic monitoring (TTM) | Arm Label: Remote; Type: ACTIVE_COMPARATOR; Interventions: Other: Medtronic CareLink® Network | Intervention Type: OTHER; Name: Transtelephonic monitoring (TTM); Assigned to Arm(s): Control | Intervention Type: OTHER; Name: Medtronic CareLink® Network; Assigned to Arm(s): Remote

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Diflunisal on Familial Amyloidosis
Brief Summary: The purpose of this study is to determine if diflunisal can prevent progressive lower leg nerve damage in patients with familial amyloidosis polyneuropathy.

Funding Source - FDA Office of Orphan Products Development (OOPD); National Institute of Neurological Disorders and Stroke (NINDS)


Options:
A: Arm Label: Fx-1006A; Type: EXPERIMENTAL; Interventions: Drug: Fx-1006A | Intervention Type: DRUG; Name: Fx-1006A; Assigned to Arm(s): Fx-1006A
B: Arm Label: Tafamidis - 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Tafamidis | Arm Label: Tafamidis - 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Tafamidis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tafamidis; Assigned to Arm(s): Tafamidis - 20 mg | Intervention Type: DRUG; Name: Tafamidis; Assigned to Arm(s): Tafamidis - 80 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Diflunisal; Type: ACTIVE_COMPARATOR; Interventions: Drug: diflunisal | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: diflunisal; Assigned to Arm(s): Diflunisal | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: Fx-1006A | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fx-1006A; Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twenty Six-week, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
Brief Summary: This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension


Options:
A: Arm Label: angiotensin receptor blockers; Type: ACTIVE_COMPARATOR; Interventions: Drug: Angiotensin receptor blockers | Arm Label: β-blockers; Type: ACTIVE_COMPARATOR; Interventions: Drug: β-blockers | Arm Label: thiazide diuretics; Type: ACTIVE_COMPARATOR; Interventions: Drug: thiazide diuretics | Intervention Type: DRUG; Name: Angiotensin receptor blockers; Assigned to Arm(s): angiotensin receptor blockers | Intervention Type: DRUG; Name: β-blockers; Assigned to Arm(s): β-blockers | Intervention Type: DRUG; Name: thiazide diuretics; Assigned to Arm(s): thiazide diuretics
B: Arm Label: Chlorthalidone plus amiloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorthalidone plus amiloride | Arm Label: losartan; Type: EXPERIMENTAL; Interventions: Drug: losartan | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): losartan | Intervention Type: DRUG; Name: Chlorthalidone plus amiloride; Assigned to Arm(s): Chlorthalidone plus amiloride
C: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Effects of doxazosin on morning surge in diabetic patients; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twenty Six-week, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
Brief Summary: This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension


Options:
A: Arm Label: Candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan, Drug: nifedipine, long acting, Drug: metoprolol, long-acting | Arm Label: Lisinopril; Type: EXPERIMENTAL; Interventions: Drug: lisinopril, Drug: nifedipine, long acting, Drug: metoprolol, long-acting | Arm Label: HCTZ; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrochlorothiazide | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): Candesartan | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): Lisinopril | Intervention Type: DRUG; Name: hydrochlorothiazide; Assigned to Arm(s): HCTZ | Intervention Type: DRUG; Name: nifedipine, long acting; Assigned to Arm(s): Candesartan, Lisinopril | Intervention Type: DRUG; Name: metoprolol, long-acting; Assigned to Arm(s): Candesartan, Lisinopril
B: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: MK0954, /Duration of Treatment : 5 Years; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator : atenolol /Duration of Treatment : 5 Years; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twenty Six-week, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
Brief Summary: This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension


Options:
A: Intervention Type: DRUG; Name: valsartan; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
C: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
D: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twenty Six-week, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
Brief Summary: This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension


Options:
A: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
C: Arm Label: Aggrenox, Clopidogrel placebo, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis | Arm Label: Aggrenox placebo, clopidogrel,, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Micardis, Drug: Aggrenox placebo, Drug: Clopidogrel | Arm Label: Aggrenox, clop placebo, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis placebo | Arm Label: Aggrenox plcebo, clop, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox placebo, Drug: Clopidogrel, Drug: Micardis placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo
D: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twenty Six-week, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
Brief Summary: This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension


Options:
A: Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Liraglutide Versus Glimepiride in Type 2 Diabetes
Brief Summary: This trial is conducted in North America (the United States of America (USA) and Mexico).

The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes. The trial is a 52-week randomised, double-blind trial period plus a 52-week open-label extension (week 104) followed by an additional 156-week continued open-label extension. The total duration of the treatment period is planned to be 260 weeks (5 years).


Options:
A: Arm Label: Lira 1.8; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Lira 1.2; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Glimepiride - 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: placebo | Arm Label: Glimepiride - 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): Glimepiride - 1, Glimepiride - 2 | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira 1.2, Lira 1.8 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glimepiride - 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glimepiride - 2
B: Intervention Type: BEHAVIORAL; Name: Insulin; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin
D: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Community Occupational Therapy on the Daily Performance of Older Patients With Mild to Moderate Dementia and on the Sense of Competence of Their Primary Caregivers.
Brief Summary: The purpose of this study is to determine the effects of community occupational therapy in older patients with mild ot moderate dementia and their primary caregivers.


Options:
A: Intervention Type: BEHAVIORAL; Name: community occupational therapy in dementia; Assigned to Arm(s): N/A
B: Arm Label: Home Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home based, flexible, stepped care intervention | Arm Label: Wait-list; Type: OTHER; Interventions: Behavioral: Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period. | Intervention Type: BEHAVIORAL; Name: Home based, flexible, stepped care intervention; Assigned to Arm(s): Home Care | Intervention Type: BEHAVIORAL; Name: Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.; Assigned to Arm(s): Wait-list
C: Intervention Type: BEHAVIORAL; Name: care management; Assigned to Arm(s): N/A
D: Arm Label: Best practices primary care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Best practices primary care | Arm Label: Home based occupational therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Home based occupational therapy | Intervention Type: BEHAVIORAL; Name: Home based occupational therapy; Assigned to Arm(s): Home based occupational therapy | Intervention Type: BEHAVIORAL; Name: Best practices primary care; Assigned to Arm(s): Best practices primary care

Answer: A